Pneumocystis pneumonia in patients with Hodgkin lymphoma

• Main Authors: T N Moiseeva, L S Al'-Radi, N N Sharkunov, N G Chernova, G A Kliasova, A N Gracheva, E A Bariakh, D S Mar'in, I V Shitareva, U L Dzhulakian, I É Kostina, M N Sinitsina, G M Galstian, S K Kravchenko
• Format: Article
• Language: Russian
• Published: "Consilium Medicum" Publishing house 2014-11-01
• Series: Терапевтический архив
• Subjects: pneumocystis pneumonia; hodgkin lymphoma
• Online Access: https://ter-arkhiv.ru/0040-3660/article/view/31654
• ISSN: 0040-3660; 2309-5342

AIM. To assess the results of diagnosing and treating Pneumocystis pneumonia (PP) in patients with Hodgkin lymphoma (HL) over 15 years. MATERIALS AND METHODS. In 1999 to 2013, PP occurred in 22 (3%) of 741 HL patients receiving programmed polychemotherapy (PCT). The male/female ratio was 1:1.1; median age was 32 (18-65) years. Advanced stages (IIB-IV) of the disease were seen in 82% of the patients. The diagnosis of PP was established when Pneumocystis (more than 5 cysts in the specimen) was detected in the lavage fluid by indirect immunofluorescence assay. RESULTS. PP developed after 4 or more cycles of PCT. Along with Pneumocystis, all the cases were found to have additional pathogens: herpes virus in 72% and bacteria and fungi in 33%. All the patients received combined antimicrobial therapy using high doses of intravenous trimethoprim-sulfamethoxazole. Ten (45%) patients required mechanical ventilation (MV). The total mortality in PP was 32% (7 patients died); moreover, none of the patients without MV died whereas the mortality among those who had MV was 70% (7 of the 10 patients died). High death rates (80%) were noted among the patients with recurrent and resistant HL. CONCLUSION. PP should be prevented with trimethoprim-sulfamethoxazole in patients with LH during PCT. If respiratory failure and X-ray signs of interstitial pneumonia appear, there is a need for fibrobronchoscopy with bronchoalveolar lavage and comprehensive microbiological testing of lavage fluid.